奎扎替尼（VANFLYTA）是一种新型口服药物，专门针对FLT3配体的靶向治疗。该药物能够有效地选择性抑制FLT3-ITD酪氨酸激酶，这 ...

据南海网报道称，吴冰是国内首例创新使用吉瑞替尼，也是首位使用博鳌研究型医院实现新药械转化，共同治疗复发性难治性FLT3突变急性髓系白血病成年患者。 海南省人民医院血液内科主任林丽娥透露，吴冰使用特许药 ...

Findings of a recent study indicate that NUP98 rearrangements can significantly impact outcomes in patients with acute myeloid leukemia (AML).

UREΔ (with PU.1 knockdown) and FLT3-ITD (with FLT3 activation) mice were used to establish collagen antibody-induced arthritis (CAIA). For the in vitro study, the effects of PU.1 and FLT3 on primary ...

根据协议，沈阳三生将获得东阳光药自主研发的克立福替尼在中国大陆关于特定适应症的独家商业化权利。公司将向东阳光药支付首付款以及研发及销售里程碑付款。东阳光药将继续负责克立福替尼的研发、注册和生产；三生制药将独家负责克立福替尼在中国大陆的商业化。

近年来，在政策鼓励创新药发展的风口下，真正具有创新能力、提供临床价值、管线推进速度走在前列的企业正脱颖而出，值博率陡增，比如差异化创新能力持续提高，积极寻求强强联合机会的东阳光长江药业。智通财经APP了解到，11月25日盘后，东阳光长江药业(0155 ...

11月25日，东阳光长江药业发布公告，公司和作为要约人的广东东阳光药业（简称东阳光药）与三生制药（01530.HK）旗下沈阳三生达成合作协议，授权沈阳三生获得公司自主研发的苯磺酸克立福替尼（简称克立福替尼）在中国大陆关于特定适应症的独家商业化权利。

Daiichi Sankyo’s Vanflyta has become the first drug in the US to be approved for newly-diagnosed acute myeloid leukaemia (AML) with FLT3-ITD mutations, nearly four years after being rejected by ...

It has been shown to work in two FLT3 mutations – namely ITD and TKD – while quizartinib only targets ITD but has greater potency against that target. “AML is a rare cancer and patients with ...

Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia TA1013 23 October 2024 23 October 2024 ...